Jump to:
Lunglife Ai, INC Fundamentals
Company Name | Lunglife Ai, INC | Last Updated | 2024-11-01 |
---|
Industry | Diagnostics & Research | Sector | Healthcare |
---|
Shares in Issue | 30.659 m | Market Cap | £2.61 m |
---|
PE Ratio | 0.00 | Dividend per Share | 0 |
---|
Dividend Yield | 0 | Dividend Cover | 0 |
---|
EPS | -$0.21 | EPS Growth (%) | 0 |
---|
PEG | 0 | DPS Growth (%) | 0 |
---|
Debt Ratio | 0.0233 | Debt Equity Ratio | 0.0037 |
---|
Asset Equity Ratio | 1.1419 | Cash Equity Ratio | 0.3301 |
---|
Quick Ratio | 2.6724 | Current Ratio | 2.83 |
---|
Price To Book Value | 0.4237 | ROCE | 0 |
---|
Lunglife Ai, INC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Lunglife Ai, INC Company Financials
Assets | 2023 | 2022 | 2021 |
---|
Tangible Assets | $389,000.00 | $566,000.00 | $766,000.00 |
Intangible Assets | $5.82 m | $5.82 m | $5.82 m |
Investments | 0 | 0 | 0 |
Total Fixed Assets | $6.22 m | $6.40 m | $6.60 m |
Stocks | 0 | 0 | 0 |
Debtors | $175,000.00 | $155,000.00 | $741,000.00 |
Cash & Equivalents | $2.83 m | $8.01 m | $14.63 m |
Other Assets | 0 | 0 | 0 |
Total Assets | $9.52 m | $15.02 m | $21.97 m |
Liabilities | 2023 | 2022 | 2021 |
---|
Creditors within 1 year | $1.45 m | $1.48 m | $1.19 m |
Creditors after 1 year | $163,000.00 | $396,000.00 | $651,000.00 |
Other Liabilities | 0 | 0 | $174,000.00 |
Total Liabilities | $1.61 m | $1.88 m | $1.84 m |
Net assets | $7.91 m | $13.14 m | $20.13 m |
Equity | 2023 | 2022 | 2021 |
---|
Called up share capital | $3,000.00 | $3,000.00 | $3,000.00 |
Share Premium | $91.27 m | $91.27 m | $91.26 m |
Profit / Loss | -$5.41 m | -$7.60 m | -$7.43 m |
Other Equity | $7.91 m | $13.14 m | $20.13 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | $7.91 m | $13.14 m | $20.13 m |
Ratios | 2023 | 2022 | 2021 |
---|
Debt Ratio | $0.01 | $0.03 | $0.03 |
Debt-to-Equity | $0.01 | $0.03 | $0.03 |
Assets / Equity | 1.1419 | 1.1419 | 1.1419 |
Cash / Equity | 0.3301 | 0.3301 | 0.3301 |
EPS | -$0.21 | -$0.30 | -$0.39 |
Cash Flow | 2023 | 2022 | 2021 |
---|
Cash from operating activities | -$5.02 m | -$5.84 m | -$7.54 m |
Cashflow before financing | -$5.32 m | -$6.10 m | $16.30 m |
Increase in Cash | -$364,000.00 | -$6.13 m | $9.09 m |
Income | 2023 | 2022 | 2021 |
---|
Turnover | $46,000.00 | $24,000.00 | $195,000.00 |
Cost of sales | 0 | 0 | $96,000.00 |
Gross Profit | $46,000.00 | $24,000.00 | $99,000.00 |
Operating Profit | -$5.63 m | -$7.74 m | -$7.23 m |
Pre-Tax profit | -$5.41 m | -$7.60 m | -$7.43 m |
Lunglife Ai, INC Company Background
Sector | Healthcare |
---|
Activities | LungLife AI Inc is focused on a developing clinical diagnostic solutions for lung cancer. The Company generates revenue from People's Republic of China and also has its presence in the United States of America. |
---|
Latest Interim Date | 22 Aug 2024 |
---|
Latest Fiscal Year End Date | 4 Apr 2024 |
---|
Lunglife Ai, INC Directors
Appointed | Name | Position |
---|
2024-04-25 | Mr. Andrew Norman Boteler | Non-Executive Director,Senior Independent Non-Executive Director |
2024-10-25 | Mr. James Renwick McCullough | Non-Executive Director |
2023-04-10 | Ms. Sara Jane Barrington | Non-Executive Director |
2024-10-22 | Dr. Paul Carmelo Pagano | Executive Director,Chief Executive Officer |
2024-04-25 | Mr. Gordon Roy Davis | Non-Executive Director,Chairman |
2024-10-22 | Mr. David Mark Anderson | Executive Director,Chief Financial Officer and Company Secretary |
Lunglife Ai, INC Contact Details
Lunglife Ai, INC Advisors